Tag Archives: pharmaceuticals
Matthew Herder considers possible regulatory responses to the opioid epidemic that aim to recover health care costs, compensate survivors, or prosecute pharmaceutical companies.
Jonathan Kimmelman comments on the recent phase 1 clinical research trial that left one healthy volunteer brain dead and five others hospitalized.
Matthew Herder shares a template letter that physicians, researchers, civil society groups, investigative journalists, and others can use to gain access to unpublished pharmaceutical safety and effectiveness data.
Matthew Herder says it is unclear whether the ‘Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law)’ will provide greater transparency in Canadian drug regulation.